Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Radius raises $15 million

This article was originally published in Scrip

Executive Summary

Radius Health, a US drug discovery company, has raised $15 million in the second tranche of a Series C investment round led by MPM Bio IV NVS Strategic Fund. Radius has raised a total of $82.5 million in the round, bringing the amount raised since the company's establishment to $106.5 million. It will use the funding to advance its clinical and preclinical development programmes, including BA058, a bone anabolic therapy for the treatment of osteoporosis, for which Radius expects Phase II trial results early next year. Radius began a Phase I trial of RAD1901, a selective oestrogen receptor modulator for the treatment of hot flushes, earlier this year and it expects to begin a Phase IIa study in the first quarter of next year. The company recently selected the first clinical candidate from its selective androgen receptor modulator discovery programmes for the treatment of muscle loss and expects to file an IND in the second quarter of next year.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC031699

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel